Brief: FDA Authorizes An Extension Of The In-Use Period For Urogen Pharma’S Jelmyto® Admixture To 96 Hours Following Reconstitution

UroGen Pharma

28/09/2022 13:02

Sept 28 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * FDA AUTHORIZES AN EXTENSION OF THE IN-USE PERIOD FOR
UROGEN
PHARMA’S JELMYTO® ADMIXTURE TO 96 HOURS FOLLOWING RECONSTITUTION
    * UROGEN PHARMA - FDA AUTHORIZED EXTENSION OF IN-USE PERIOD
FOR
JELMYTO FOR PYELOCALYCEAL SOLUTION ADMIXTURE FROM 8 HOURS TO 96
HOURS AFTER RECONSTITUTION OF PRODUCT

Source text for Eikon:  ID:nBw88SFF3a 
Further company coverage:  UR8.F 
 ((Reuters.Briefs@thomsonreuters.com;;))